Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update
Bei Hu, Praveen Vikas, Mohamad Mohty, et al.
Expert Review of Hematology (2013) Vol. 7, Iss. 2, pp. 301-315
Closed Access | Times Cited: 17

Showing 17 citing articles:

Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT
Panagiotis Tsirigotis, Michael Byrne, Christoph Schmid, et al.
Bone Marrow Transplantation (2016) Vol. 51, Iss. 11, pp. 1431-1438
Open Access | Times Cited: 187
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS
Christopher G. Kanakry, Hua-Ling Tsai, Javier Bolaños‐Meade, et al.
Blood (2014) Vol. 124, Iss. 25, pp. 3817-3827
Open Access | Times Cited: 183
Hematopoietic stem cell transplantation for acute myeloid leukemia: A review
Adetola A. Kassim, B. Savani
Hematology/Oncology and Stem Cell Therapy (2017) Vol. 10, Iss. 4, pp. 245-251
Open Access | Times Cited: 60
Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia
Naveen Pemmaraju, Hagop M. Kantarjian, Michael Andreeff, et al.
Expert Opinion on Investigational Drugs (2014) Vol. 23, Iss. 7, pp. 943-954
Open Access | Times Cited: 28
Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia
Anna Candoni, Federico De Marchi, Francesca Zanini, et al.
Experimental Hematology (2017) Vol. 49, pp. 25-33
Open Access | Times Cited: 24
The Genomic Era of Clinical Oncology: Integrated Genomic Analysis for Precision Cancer Care
Lea F. Surrey, Minjie Luo, Fengqi Chang, et al.
Cytogenetic and Genome Research (2016) Vol. 150, Iss. 3-4, pp. 162-175
Open Access | Times Cited: 22
Use of sorafenib for post-transplant relapse in FLT3/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect
Jessica Liegel, Elizabeth L. Courville, Zohar Sachs, et al.
Haematologica (2014) Vol. 99, Iss. 11, pp. e222-e224
Open Access | Times Cited: 21
Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature
Kelly J. Norsworthy, Amy E. DeZern, Hua-Ling Tsai, et al.
Leukemia Research (2017) Vol. 61, pp. 25-32
Open Access | Times Cited: 11
Mild chronic graft‐versus‐host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study
Barbara Nasiłowska‐Adamska, Anna Czyż, Mirosław Markiewicz, et al.
European Journal Of Haematology (2015) Vol. 96, Iss. 3, pp. 236-244
Open Access | Times Cited: 9
Optimal Therapy for Adult Patients with Acute Myeloid Leukemia in First Complete Remission
Peter H. Wiernik
Current Treatment Options in Oncology (2014) Vol. 15, Iss. 2, pp. 171-186
Closed Access | Times Cited: 8
Approach to AML Treatment. Survey Results from the 6th International Hematologic Malignancies Conference: Bridging the gap 2015,Beijing,China
Kaiyan Liu Pankaj Malhotra
Journal of Leukemia (2015) Vol. 03, Iss. 02
Open Access | Times Cited: 3
The Challenge of t(6;9) and FLT3-Positive Acute Myelogenous Leukemia in a Young Adult
Yeohan Song, Dale L. Bixby, Diane Roulston, et al.
Journal of Leukemia (2014) Vol. 02, Iss. 05
Open Access | Times Cited: 3
[Efficacy and safety of Sorafenib as monotherapy to FLT3-ITD positive acute myeloid leukemia].
Jun Jia, Hua-Yuan Zhu, Huaping Fu, et al.
PubMed (2016) Vol. 37, Iss. 12, pp. 1022-1026
Closed Access | Times Cited: 2
[Efficacy and safety of gilteritinib combined with chemotherapy in newly diagnosed FLT3-mutated acute myeloid leukemia].
Lei Yue, Xinyi Zhao, Ming Hong, et al.
PubMed (2024) Vol. 45, Iss. 12, pp. 1129-1133
Closed Access
Inching toward cure of acute myeloid leukemia: a summary of the progress made in the last 50 years
Peter H. Wiernik
Medical Oncology (2014) Vol. 31, Iss. 8
Closed Access | Times Cited: 2
[Sorafenib in combination with chemotherapy as induction therapy for FLT3-ITD positive acute myeloid leukemia:nine cases report and literatures review].
Sha Liu, Xudong Wei, Qingsong Yin, et al.
PubMed (2015) Vol. 36, Iss. 3, pp. 241-4
Closed Access | Times Cited: 1
[Analysis of induction efficacy and prognostic factors in FLT3-ITD positive acute myeloid leukemia in the real world].
Jun Jia, Hua-Yuan Zhu, Lizhong Gong, et al.
PubMed (2019) Vol. 40, Iss. 5, pp. 398-403
Closed Access
Page 1

Scroll to top